Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Percheron Therapeutics ( (AU:PER) ) is now available.
Percheron Therapeutics has secured an exclusive worldwide license from Hummingbird Bioscience for HMBD-002, a phase II-ready immuno-oncology drug candidate targeting VISTA, a novel checkpoint in cancer treatment. This strategic move positions Percheron to advance in the immuno-oncology field, with plans to initiate clinical trials in 2026, potentially offering new therapeutic options for cancer patients.
The most recent analyst rating on (AU:PER) stock is a Buy with a A$0.24 price target. To see the full list of analyst forecasts on Percheron Therapeutics stock, see the AU:PER Stock Forecast page.
More about Percheron Therapeutics
Percheron Therapeutics Limited is an international biotechnology company focused on developing novel therapies for oncology and rare diseases.
Average Trading Volume: 2,079,348
Technical Sentiment Signal: Sell
Current Market Cap: A$10.87M
For detailed information about PER stock, go to TipRanks’ Stock Analysis page.